Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Preferential Generation of Follicular B Helper T Cells from Foxp3 + T Cells in Gut Peyer's Patches
2009 StandoutScienceNobel
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
2018
Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy
2011 StandoutNobel
Activation-induced cytidine deaminase mediates central tolerance in B cells
2011
Telomerase-Specific T-Cell Immunity in Breast Cancer: Effect of Vaccination on Tumor Immunosurveillance
2007
Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell Depletion
2010 StandoutNobel
Follicular helper T cells are required for systemic autoimmunity
2009
PEST Domain-Enriched Tyrosine Phosphatase (PEP) Regulation of Effector/Memory T Cells
2004 Science
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
2007
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
2010 Standout
A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity
2009
Systemic Targeting of CpG-ODN to the Tumor Microenvironment with Anti–neu-CpG Hybrid Molecule and T Regulatory Cell Depletion Induces Memory Responses in BALB-neuT Tolerant Mice
2008 StandoutNobel
HER‐2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell‐mediated anti‐tumor immune responses
2007
Engineered receptors for soluble cellular communication and disease sensing
2024 StandoutNatureNobel
Immunosurveillance ofErbb2Carcinogenesis in Transgenic Mice Is Concealed by a Dominant Regulatory T-Cell Self-Tolerance
2006
EGFR Antagonists in Cancer Treatment
2008 Standout
Immunological Memory Stabilizing Autoreactivity
2006
Activation-Induced Cytidine Deaminase Deficiency Causes Organ-Specific Autoimmune Disease
2008
Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer
2014
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity
2000
A Consideration of Biomarkers to be Used for Evaluation of Inflammation in Human Nutritional Studies
2013
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Transforming Growth Factor-β Signaling in Immunity and Cancer
2019 Standout
Pathologic and Radiologic Differences Between Idiopathic and Collagen Vascular Disease-Related Usual Interstitial Pneumonia
2009
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Coordinated regulation of myeloid cells by tumours
2012 Standout
Cancer immunotherapy via dendritic cells
2012 Standout
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus
2009
Personalized cancer vaccines: Targeting the cancer mutanome
2016
Follicular B helper T cells in antibody responses and autoimmunity
2005
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
The E75 HER2/neu peptide vaccine
2008
Regulatory T Cells Control Antigen-Specific Expansion of Tfh Cell Number and Humoral Immune Responses via the Coreceptor CTLA-4
2014 StandoutNobel
Emerging Biological Principles of Metastasis
2017 Standout
Activation-Induced Cytidine Deaminase Expression in CD4+ T Cells is Associated with a Unique IL-10-Producing Subset that Increases with Age
2011 StandoutNobel
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Genetics of Systemic Autoimmunity in Mouse Models of Lupus
2000
IgG4-related disease
2014 Standout
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
2012 StandoutNobel
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
2013 Standout
Protein Tyrosine Phosphatases in the Human Genome
2004 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Idiopathic pulmonary fibrosis
2011 Standout
In Vivo Analysis of Aicda Gene Regulation: A Critical Balance between Upstream Enhancers and Intronic Silencers Governs Appropriate Expression
2013 StandoutNobel
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Bifidobacteria can protect from enteropathogenic infection through production of acetate
2011 StandoutNature
Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
2011
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung
2011
Mechanisms for oncogenic activation of the epidermal growth factor receptor
2007
Interleukin 17–producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice
2007
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
2009 Standout
Impaired apoptosis, extended duration of immune responses, and a lupus-like autoimmune disease in IEX-1-transgenic mice
2002 StandoutNobel
Attenuation of CD8+ T-Cell Function by CD4+CD25+ Regulatory T Cells in B-Cell Non-Hodgkin's Lymphoma
2006
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
Current concepts in the diagnosis and management of cytokine release syndrome
2014 Standout
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Strain-Specific Manifestation of Lupus-like Systemic Autoimmunity Caused by Zap70 Mutation
2019 StandoutNobel
Augmented IL-15Rα Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice
2012 StandoutNobel
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
2011 StandoutNobel
Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy
2011
Loss of the Protein Tyrosine Phosphatase PTPN22 Reduces Mannan-Induced Autoimmune Arthritis in SKG Mice
2016 StandoutNobel
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
IL-17 and Th17 Cells
2009 Standout
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model
2012 StandoutNobel
Cytokine Storm
2020 Standout
Circulating Follicular Helper–Like T Cells in Systemic Lupus Erythematosus: Association With Disease Activity
2015
Chimeric Antigen Receptor Therapy
2018 Standout
T Follicular Helper (TFH) Cells in Normal and Dysregulated Immune Responses
2008
Conversion of Alloantigen-Specific CD8+ T Cell Anergy to CD8+ T Cell Priming through In Vivo Ligation of Glucocorticoid-Induced TNF Receptor
2006 StandoutNobel
Regulatory roles of IL-10–producing human follicular T cells
2019 StandoutNobel
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Differentiation of Effector CD4 T Cell Populations
2010 Standout
Works of Catherine E. Storrer being referenced
Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer
2006
Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients
2005
Direct Measurement of Peptide-Specific CD8+ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer Patients
2004
Evaluation of the HER2/neu‐derived peptide GP2 for use in a peptide‐based breast cancer vaccine trial
2006
Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex® technology
2007
Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients
2006
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
2008
Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides
2005
Further Characterization of the Autoantibody Response of Palmerston North Mice
1999
Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer
2006
Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine★
2006
Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine
2006
Combined Clinical Trial Results of a HER2/neu(E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
2008
Spontaneous formation of germinal centers in autoimmune mice
2001
Vasculitis in the Palmerston North mouse model of lupus: Phenotype and cytokine production profile of infiltrating cells
1999
Developing a predictive model for disease status in breast cancer patients using Th1 and Th2 serum cytokine profiles
2006
Early results of a phase I clinical trial of an Ii-Key/Her2/neu MHC class II peptide-based vaccine in breast cancer patients
2006
Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients
2005
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients
2005